Talk about a drug industry blockbuster. Over the past decade the market value of Fortune 500 pharmaceutical companies has nearly doubled, to $1.5 trillion, thanks largely to the explosive growth of biotechnology firms. In 2004 there was just one true biotech name—Amgen—on the list. Today there are seven, with a combined market cap that is fast approaching that of the old-guard Big Pharma companies.